| [1] |
Dounousi E,Duni A,Leivaditis K, et al. Improvements in the management of diabetic nephropathy[J]. Rev Diabet Stud, 2015, 12(1-2): 119-133.
|
| [2] |
Lamine F,Lalubin F,Pitteloud N, et al. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs[J]. Swiss Med Wkly, 2016, 146: w14282.
|
| [3] |
Zoungas S,de Galan BE,Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial[J]. Diabetes Care, 2009, 32(11): 2068-2074.
|
| [4] |
Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
|
| [5] |
Flynn C,Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis[J]. Nat Rev Nephrol, 2013, 9(3): 147-153.
|
| [6] |
Niemi M,Backman JT,Juntti-Patinen L, et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide[J]. Br J Clin Pharmacol, 2005, 60(2): 208-217.
|
| [7] |
Pernicova I,Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer[J]. Nat Rev Endocrinol, 2014, 10(3): 143-156.
|
| [8] |
Górriz JL,Nieto J,Navarro-González JF, et al. Nephroprotection by hypoglycemic agents: Do we have supporting data?[J]. J Clin Med, 2015, 4(10): 1866-1889.
|
| [9] |
Venos ES,Sigal RJ. My patient′s diabetic kidney disease has progressed to stage 4; should I discontinue metformin?[J]. Can J Diabetes, 2014, 38(5): 296-299.
|
| [10] |
Lipska KJ,Bailey CJ,Inzucchi SE. Metformin in patients with type 2 diabetes and kidney disease: a systematic review[J]. JAMA, 2014, 312(24): 2668-2675.
|
| [11] |
Ekstrom N,Schioler L,Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register[J]. BMJ Open, 2012, 2(4): e001076.
|
| [12] |
Lipska KJ,Bailey CJ,Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency[J]. Diabetes Care, 2011, 34(6): 1431-1437.
|
| [13] |
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J]. Am J Kidney Dis, 2007, 49(2 Suppl 2): S12-S154.
|
| [14] |
Chapelsky MC,Thompson-Culkin K,Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency[J]. J Clin Pharmacol, 2003, 43(3): 252-259.
|
| [15] |
Flynn C,Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis[J]. Nat Rev Nephrol, 2013, 9(3): 147-153.
|
| [16] |
Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
|
| [17] |
Game F. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease[J]. Nephron Clin Pract, 2014, 126(1): 14-18.
|
| [18] |
Yew T,Toh SA,Millar JS. Selective peroxisome proliferator-activated receptor-gamma modulation to reduce cardiovascular risk in patients with insulin resistance[J]. Recent Pat Cardiovasc Drug Discov, 2012, 7(1): 33-41.
|
| [19] |
Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus[J]. Diabetes Educ, 2006, 32(6): 869-876.
|
| [20] |
Abe M,Kikuchi F,Kaizu K, et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis[J]. Clin Nephrol, 2007, 68(5): 287-294.
|
| [21] |
Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
|
| [22] |
Herzlinger S,Horton ES. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes[J]. Diabetes Res Clin Pract, 2013, 100(1): 1-10.
|
| [23] |
Makino Y,Fujita Y,Haneda M. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease[J]. Curr Opin Nephrol Hypertens, 2015, 24(1): 67-73.
|
| [24] |
Herman GA,Bergman A,Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2006, 91(11): 4612-4619.
|
| [25] |
Reilly JB,Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease[J]. Semin Dial, 2010, 23(2): 163-168.
|
| [26] |
Boulton DW,Li L,Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin[J]. Clin Pharmacokinet, 2011, 50(4): 253-265.
|
| [27] |
Inzucchi SE,Bergenstal RM,Buse JB, et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2012, 35(6): 1364-1379.
|
| [28] |
Cheng D,Fei Y,Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: A systematic review and meta-analysis[J]. PLoS One, 2014, 9(10): e111543.
|
| [29] |
Yale J-F,Bakris G,Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease[J]. Diabetes Obes Metab, 2013, 15(5): 463-473.
|